With autologous CTLs enriched for specificity to LMP1& LMP2 Ags, durable clinical response without toxicity in heavily pre-treated patients with EBV-associated lymphoma was observed. In patients with recurrent NPC, regression of the majority of pulmonary lesions were indicated. The gene discussed is PSMB9; the disease is lymphoma.